文献速递糖尿病肥胖与代谢综合征

糖尿病中的高脂血症:下一代疗法是否有特殊考虑?

Hyperlipidaemia in diabetes: are there particular considerations for next-generation therapies?
PubMed 文献 · Diabetologia · 2024-02-20

综述讨论靶向脂蛋白代谢的下一代降脂疗法在糖尿病与糖尿病前期人群中的疗效及对血糖控制的影响,并关注新发糖尿病风险与心血管高危人群中的治疗考虑。

要点

  • 下一代降脂疗法包括抗PCSK9抗体、靶向PCSK9的siRNA、贝派地酸、靶向载脂蛋白C-III的反义寡核苷酸、抗血管生成素样蛋白3抗体及二十碳五烯酸乙酯。
  • 自2008年提出强化他汀治疗可能增加新发糖尿病风险后,每种新降脂疗法均在评估其新发糖尿病风险,尤其关注糖尿病前期人群。
  • 糖尿病患者占心血管高危或极高危人群的很大比例,需密切考虑这些药物在糖尿病亚组中的疗效及对血糖控制的潜在影响。

核心结论

  • 综述描述靶向脂蛋白代谢的下一代疗法在糖尿病亚组中的疗效及其对糖尿病、糖尿病前期和血糖正常个体血糖控制的影响。

研究设计与样本

  • 综述,检索范围未报告。

主要发现

  • 下一代疗法包括抗PCSK9抗体、靶向PCSK9的siRNA、靶向ATP柠檬酸裂解酶的贝派地酸、靶向载脂蛋白C-III的反义寡核苷酸、抗血管生成素样蛋白3抗体及纯化omega-3脂肪酸二十碳五烯酸乙酯。
  • 自2008年首次提出强化他汀治疗增加新发糖尿病风险后,每种新降脂疗法均在评估新发糖尿病风险,尤其关注糖尿病前期(空腹血糖受损和/或糖耐量受损)个体。
  • 糖尿病患者占当前或将来处方这些降脂药的心血管高危或极高危人群的很大比例,需密切考虑药物在糖尿病亚组中的疗效及对血糖控制的潜在影响。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Dyslipidaemias are major cardiovascular risk factors, especially in people with diabetes. In this area, next-generation therapies targeting circulating lipoparticle metabolism (LDL, VLDL, chylomicrons, HDL) have recently been approved by the European and US medical agencies, including anti- proprotein convertase subtilisin/kexin 9 (PCSK9) antibodies; an siRNA targeting PCSK9; bempedoic acid, which targets ATP citrate lyase; an antisense oligonucleotide targeting apolipoprotein C-III; an anti-angiopoietin-like 3 antibody; and a purified omega-3 fatty acid, icosapent ethyl. Other therapies are in different phases of development. There are several important considerations concerning the link between these new lipid-lowering therapies and diabetes. First, since concerns were first raised in 2008 about an increased risk of new-onset diabetes mellitus (NODM) with intensive statin treatment, each new lipid-lowering therapy is being evaluated for its associated risk of NODM, particularly in individuals with prediabetes (impaired fasting glucose and/or impaired glucose tolerance). Second, people with diabetes represent a large proportion of those at high or very high cardiovascular risk in whom these lipid-lowering drugs are currently, or will be, prescribed. Thus, the efficacy of these drugs in subgroups with diabetes should also be closely considered, as well as any potential effects on glycaemic control. In this review, we describe the efficacy of next-generation therapies targeting lipoprotein metabolism in subgroups of people with diabetes and their effects on glycaemic control in individuals with diabetes and prediabetes and in normoglycaemic individuals.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Béliard S, Mourre F, Valéro R, et al. Hyperlipidaemia in diabetes: are there particular considerations for next-generation therapies? Diabetologia. 2024. PMID: 38376536. doi:10.1007/s00125-024-06100-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。